logo
Plus   Neg
Share
Email

AstraZeneca: Fasenra Gets FDA's ODD For Hypereosinophilic Syndrome - Quick Facts

British drug maker AstraZeneca Plc (AZN.L,AZN) announced Wednesday that the US Food and Drug Administration or FDA has granted Orphan Drug Designation or ODD to Fasenra (benralizumab) for the treatment of hypereosinophilic syndrome or HES.

The company noted that HES is a group of rare, potentially fatal disorders characterised by high numbers of eosinophils in blood and tissues, which can cause progressive damage to any organ in the body.

The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US.

A Phase II clinical trial of Fasenra for the treatment of HES has been conducted by the US National Institutes of Health in collaboration with AstraZeneca, with results expected to be published later in 2019. In the trial, Fasenra depleted blood eosinophils at week 12 compared with placebo, the primary endpoint of the trial, with evidence of eosinophil clearance in affected tissue at week 24.

Fasenra is AstraZeneca's first respiratory biologic and is currently approved as an add-on maintenance treatment for severe, eosinophilic asthma in the US, EU, Japan and several other countries. In November 2018, the FDA granted ODD for Fasenra for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA).

The goal of HES treatment is to reduce eosinophils in the blood and tissues, prevent organ damage and slow disease progression. HES treatment typically includes glucocorticoids, immunomodulatory therapies and cytotoxic therapies.

Fasenra was developed by AstraZeneca with MedImmune, and is in-licensed from BioWa, Inc., a subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan.

For comments and feedback contact: editorial@rttnews.com

FDA/Panel Decisions

1 Articles
Follow RTT